Marinus Pharmaceuticals Inc (MRNS) Earnings Report, Financial Results, Financial analysis

Marinus Pharmaceuticals inc narrowed IV. Quarter net loss per share of $-0.72 compare to net loss per share of $-0.77 recorded in the same quarter a year ago a decrease from $1.89 eps realized in III. Quarter (Sep 30 2022).

*IV. Quarter*
Earnings Per Share	Revenues
$ -0.72	$ 7 Mill
$+0.05	$+6M +371.18 %

Marinus Pharmaceuticals Inc 's Revenue rose by 371.18 % in IV. Quarter (Dec 31 2022) year on year, to $7 million and advanced by 206.07 % sequentially.

Marinus Pharmaceuticals Inc is Expected to report next financial results on March 23, 2023.

More on MRNS's Income Statement

MRNS's NET INCOME

Marinus Pharmaceuticals Inc 's in IV. Quarter recorded net loss of $-32.656 million, an increase from net loss of $-28.305 million in IV. Quarter a year ago.

Sequentially company realized net loss, compare to net income of $71.634 million in previous quarter.

More on MRNS's Growth

Marinus Pharmaceuticals Inc Inventories
In IV. Quarter company's net cash and cash equivalents decreased by $0 million

Earnings quality

Marinus Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Marinus Pharmaceuticals inc payed $ -2.34 cash per share, on a free-cash flow basis .

Book value grew by 38.02 % sequentially to $2.99 per share.
Tangible Book value grew to $ 2.88 per share from $ 2.06.

Company issued 0.94 million shares or 2.49 % in IV. Quarter.

• More on MRNS's Dividends

Market Capitalization (Millions)	242
Shares Outstanding (Millions)	39
Total Debt (Millions $)	71
Revenue (TTM) (Millions $)	25
Net Income (TTM) (Millions $)	-20
Cash Flow (TTM) (Millions $)	45
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Marinus Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Marinus Pharmaceuticals inc had negative $ -2.34 cash flow per share, on a free-cash flow basis .

Book value grew by 38.02 % sequentially to $2.99 per share.
Tangible Book value grew to $ 2.88 per share from $ 2.06.

Company issued 0.94 million shares or 2.49 % in IV. Quarter.

• More on MRNS's Balance Sheets

Market Capitalization (Millions)	242
Shares Outstanding (Millions)	39
Total Debt (Millions $)	71
Revenue (TTM) (Millions $)	25
Net Income (TTM) (Millions $)	-20
Cash Flow (TTM) (Millions $)	45
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar GETY's Profile Stock Price GETY's Financials Business Description Fundamentals Charts & Quotes GETY's News Suppliers GETY's Competitors Customers & Markets Economic Indicators GETY's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Marinus Pharmaceuticals inc

MRNS's Financial Statements and Analysis